At Angiodroid, commitment is more than a value—it is the principle inspiring every innovation in CO2 angiography.
We empower clinicians with safer, reliable, renal-friendly imaging solutions designed for the patients who need them most.
For Angiodroid, commitment is a discipline. It means delivering technologies that are scientifically sound, operationally efficient, and clinically meaningful. It also means understanding the daily challenges of vascular specialists—and responding with clarity, precision, and responsibility.
Our goal is simple: to make safer imaging the global standard of care. Through advanced CO2 delivery systems and continuous research collaboration, we support clinical decision-making where iodinated contrast agents carry unnecessary risk.
Excellence is not an achievement, but a continuous process. We invest in engineering, training, and clinical support to ensure that every Angiodroid system delivers reliability, reproducibility, and operational fluency.
We stand with a global community of clinicians who believe in a safer approach to vascular imaging. Through shared experiences, evidence, and innovation, we are shaping a new culture of responsible angiography.
Our commitment is tangible and measurable. We collaborate with clinical partners worldwide to improve outcomes and make safer imaging practices broadly available.
From humble beginnings to increasingly ambitious goals, Angiodroid has been constanstly raising the bar of what's attainable.
Just like all living beings, we grow and adapt to become the best version of ourselves.
Protecting the more fragile patients and their kidneys is the main driver our company.
As ICM is one of the main casuses of CIN and allergic reactions, Carbon Dioxide has been used since 1971 as unique and most valid alternative to iodine contrast medium in angiography for its totally un-allergic and non-toxic qualities; this is what led Sebastiano Zannoli to found Angiodroid in 2013.
Since then, our mission has taken us all over the world.
Our automated CO₂ injection system has since been validated by multiple studies, making it more than a simple alternative to ICM: sometimes, it's the only way to go.
Throughout the years, the imaging technology has improved to a point that already impressive CO₂ images are virtually indistiguishable from ICM ones. This is a comparison between ICM and CO₂:

As the world changes, so are we; we're proud to be part of some groundbreaking clinical trials that aim to make the world a safer and healthier place, including:
In the meantime, as Angiodroid reached its 10th year, the company turned from Srl (Limited Liability Company) to SpA (Joint Stock Company); looking back, we went a long way. Looking forward, we still have a long way to go, and we'll always have, because evolution never stops.
